Publications by authors named "Sandrine d'Argouges"

Claim this Profile
H
How useful are 3-month repeat-dose toxicology studies for the development of T cell engagers for oncology indications?
Petra Lutterbuese, Sandrine d'Argouges, Matthias Friedrich, Christine Mollica, Famke Aeffner

Regul Toxicol Pharmacol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The interleukin-2 antagonizing antibody MT204 delays allogeneic skin graft rejection in non-human primates and is well tolerated.
Christine Plater-Zyberk, Dave M Lopes Estêvão, Sandrine d'Argouges, Krista G Haanstra, Ivanela Kondova

Transpl Immunol· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release.
Maria Amann, Sandrine D'Argouges, Grit Lorenczewski, Klaus Brischwein, Roman Kischel

J Immunother· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells.
Sandrine d'Argouges, Sandra Wissing, Christian Brandl, Nadja Prang, Ralf Lutterbuese

Leuk Res· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct.
Christian Brandl, Cornelia Haas, Sandrine d'Argouges, Tanja Fisch, Peter Kufer

Cancer Immunol Immunother· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis